Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q4 2019 Results - Earnings Call Transcript
Feb. 25, 2020 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Inc (HALO) Q4 2019 Earnings Call Transcript
Feb. 24, 2020 | Price: Free! | Source: Motley Fool

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2019 Results - Earnings Call Transcript
Nov. 13, 2019 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call Transcript
Nov. 12, 2019 | Price: Free! | Source: Motley Fool

Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript
Aug. 8, 2019 | Price: Free! | Source: Motley Fool

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2019 Results - Earnings Call Transcript
Aug. 6, 2019 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2019 Results - Earnings Call Transcript
May 7, 2019 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. (HALO) CEO Dr. Helen Torley on Q4 2018 Results - Earnings Call Transcri
Feb. 21, 2019 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2018 Results - Earnings Call Transcript
Nov. 6, 2018 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2018 Results - Earnings Call Transcript
Aug. 8, 2018 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript
May 10, 2018 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2017 Results - Earnings Call Transcript
Feb. 21, 2018 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Dr. Helen Torley on Q3 2017 Results - Earnings Call Transcript
Nov. 7, 2017 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Presents at 2017 Wells Fargo Healthcare Conference (Transcript)
Sept. 13, 2017 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2017 Results - Earnings Call Transcript
Aug. 8, 2017 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2017 Results - Earnings Call Transcript
May 9, 2017 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2016 Results - Earnings Call Transcript
Feb. 28, 2017 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2016 Results - Earnings Call Transcript
Nov. 7, 2016 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2016 Results - Earnings Call Transcript
Aug. 9, 2016 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2016 Results - Earnings Call Transcript
May 9, 2016 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2015 Results - Earnings Call Transcript
Feb. 29, 2016 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2015 Results - Earnings Call Transcript
Nov. 9, 2015 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2015 Results - Earnings Call Transcript
Aug. 10, 2015 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2014 Results - Earnings Call Transcript
May 11, 2015 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2014 Results - Earnings Call Transcript
March 2, 2015 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2014 Results - Earnings Call Transcript
Aug. 11, 2014 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2014 Results - Earnings Call Transcript
May 12, 2014 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Management Discusses Q4 2013 Results - Earnings Call Transcript
Feb. 27, 2014 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. - 32nd Annual J.P. Morgan Healthcare Conference Transcript
Jan. 16, 2014 | Price: Free! | Source: Earnings Impact

Halozyme Therapeutics' CEO Presents At Piper Jaffray Healthcare Conference (Transcript)
Dec. 3, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q3 2013 Earnings Conference Call Transcript
Nov. 8, 2013 | Price: $106.00 | Source: Thomson

Halozyme Therapeutics Management Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 8, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. - Q3 2013 Earnings Call Transcript
Nov. 8, 2013 | Price: Free! | Source: Earnings Impact

Halozyme's CEO Presents at BioCentury NewsMakers in the Biotech Industry Conference (Transcript)
Sept. 27, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. at BioCentury NewsMakers in the Biotech Industry Conference Transcript
Sept. 27, 2013 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics, Inc. - Q2 2013 Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Earnings Impact

Halozyme Therapeutics, Inc. Management Discusses Q2 2013 Results (Webcast)
Aug. 7, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q2 2013 Earnings Conference Call Transcript
Aug. 7, 2013 | Price: $106.00 | Source: Thomson

Halozyme Therapeutics Management Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (
May 15, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2013 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript
May 8, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q1 2013 Earnings Conference Call Transcript
May 8, 2013 | Price: $106.00 | Source: Thomson

Halozyme Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2013 04:15 PM
March 12, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. at Barclays Healthcare Conference Transcript
March 12, 2013 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics, Inc. Q4 2012 Earnings Conference Call Transcript
Feb. 25, 2013 | Price: $106.00 | Source: Thomson

Halozyme Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcript
Feb. 25, 2013 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. at JPMorgan Global Healthcare Conference Transcript
Jan. 10, 2013 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics Management Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 8, 2012 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q3 2012 Earnings Conference Call Transcript
Nov. 8, 2012 | Price: $106.00 | Source: Thomson

Halozyme Therapeutics, Inc. Analyst Meeting Transcript
Oct. 2, 2012 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics's CEO Hosts Analyst/Investor Day Conference Call (Transcript)
Oct. 2, 2012 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript
Aug. 6, 2012 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q2 2012 Earnings Conference Call Transcript
Aug. 6, 2012 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics, Inc. to Host Conference Call Providing Regulatory Update on Plasma-Derived S
Aug. 1, 2012 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics, Inc. at Jefferies Global Healthcare Conference Transcript
June 7, 2012 | Price: $54.00 | Source: Thomson

Halozyme Therapeutics, Inc.(HALO) Q1 2012 Earnings Call Transcript
May 7, 2012 | Price: Free! | Source: Morningstar

Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
Nov. 6, 2009 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q4 2008 Earnings Call Transcript
March 13, 2009 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics, Inc. Q3 2008 Earnings Call Transcript
Nov. 19, 2008 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Inc. Q2 2008 Earnings Call Transcript
Aug. 8, 2008 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Inc. Q1 2008 Earnings Call Transcript
May 9, 2008 | Price: Free! | Source: Seeking Alpha

Halozyme Therapeutics Q4 2007 Earnings Call Transcript
March 14, 2008 | Price: Free! | Source: Seeking Alpha

Recent filings

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - March 20, 2020

Other definitive proxy statements - March 20, 2020

Halozyme Therapeutics director just picked up 52,629 shares - March 19, 2020

SVP of Halozyme Therapeutics was just granted 153,631 options and restricted shares - March 4, 2020

SVP of Halozyme Therapeutics just declared 0 ownership of the company. - March 4, 2020

SVP of Halozyme Therapeutics just picked up 6,884 shares - Feb. 24, 2020

Halozyme Therapeutics's President and CEO just picked up 19,843 shares - Feb. 24, 2020

Halozyme: Quarter And Full Year RESULTS - Feb. 24, 2020

Departure of Directors or Certain - Feb. 24, 2020

Halozyme Therapeutics Just Filed Its Annual Report: Net (Loss) Income Pe... - Feb. 24, 2020

SVP of Halozyme Therapeutics just picked up 5,759 shares - Feb. 24, 2020

Halozyme Therapeutics's President and CEO just picked up 14,486 shares - Feb. 18, 2020

SVP of Halozyme Therapeutics just picked up 3,777 shares - Feb. 18, 2020

SVP of Halozyme Therapeutics just picked up 5,109 shares - Feb. 18, 2020

BB Biotech AG just provided an update on share ownership of Halozyme Therapeutics - Feb. 14, 2020

SVP of Halozyme Therapeutics just picked up 5,158 shares - Feb. 13, 2020

SVP of Halozyme Therapeutics just picked up 7,368 shares - Feb. 13, 2020

SVP of Halozyme Therapeutics just picked up 2,449 shares - Feb. 13, 2020

Halozyme Therapeutics's President and CEO just picked up 16,536 shares - Feb. 13, 2020

SVP of Halozyme Therapeutics was just granted 78,237 options and restricted shares - Feb. 12, 2020

Halozyme Therapeutics's President and CEO was just granted 391,177 options and restricted shares - Feb. 12, 2020

SVP of Halozyme Therapeutics was just granted 101,707 options and restricted shares - Feb. 12, 2020

SVP of Halozyme Therapeutics was just granted 101,707 options and restricted shares - Feb. 12, 2020

The Vanguard Group just provided an update on share ownership of Halozyme Therapeutics - Feb. 10, 2020

The Vanguard Group just provided an update on share ownership of Halozyme Therapeutics - Feb. 10, 2020

SVP of Halozyme Therapeutics just picked up 14,844 shares - Feb. 4, 2020

SVP of Halozyme Therapeutics just picked up 7,270 shares - Feb. 4, 2020

Halozyme Therapeutics's President and CEO just disposed of 12,500 shares - Feb. 4, 2020

Halozyme Therapeutics's President and CEO just picked up 35,577 shares - Feb. 4, 2020

. Iridian Asset Management LLC just provided an update on share ownership of Halozyme Therapeutics - Jan. 28, 2020

38Th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. Dr. Helen Torley, President And Ceo January 16, 2020 - Jan. 16, 2020

Halozyme Provides 2020 Business Update And Financial Guidance - Jan. 14, 2020

SVP of Halozyme Therapeutics just declared owning 4,489 shares of Halozyme Therapeutics - Jan. 6, 2020

SVP of Halozyme Therapeutics just declared owning 154,223 shares of Halozyme Therapeutics - Jan. 6, 2020

Entry into a Material Definitive - Nov. 18, 2019

Halozyme Therapeutics, Inc. Announces Pricing Of Private Offering Of - Nov. 14, 2019

Costs Associated with Exit or Disposal - Nov. 12, 2019

Halozyme Therapeutics Just Filed Its Quarterly Report: Net Loss Per ShareBa... - Nov. 12, 2019

Halozyme Therapeutics, Inc. Announces Proposed Offering Of $400 Million - Nov. 12, 2019

Halozyme: - Total Revenues Increase - Nov. 12, 2019

RANDAL J. KIRK just provided an update on activist position in Halozyme Therapeutics - Nov. 5, 2019

Costs Associated with Exit or Disposal - Nov. 5, 2019

SVP of Halozyme Therapeutics just picked up 13,226 shares - Oct. 1, 2019

Halozyme: 2019 Wells Fargo Healthcare Conference Building A Premier Oncology Biotech Dr. Helen Torley, President And Ceo September 4, 2019 - Sept. 4, 2019

Halozyme: - Total Revenues Increase - Aug. 6, 2019

Halozyme Therapeutics Just Filed Its Quarterly Report: Net Loss Per ShareBa... - Aug. 6, 2019

SVP of Halozyme Therapeutics just disposed of 1,328 shares - Aug. 5, 2019

RANDAL J. KIRK just provided an update on activist position in Halozyme Therapeutics - July 3, 2019

SVP of Halozyme Therapeutics just picked up 3,467 shares - June 17, 2019

clinical trial and that it plans to conduct the final overall survival analysis upon data maturity which will occur when all patients enrolled in the study have been followed for at least - June 12, 2019

RANDAL J. KIRK just provided an update on activist position in Halozyme Therapeutics - June 7, 2019

SVP of Halozyme Therapeutics was just granted 195,278 options and restricted shares - June 4, 2019

SVP of Halozyme Therapeutics just picked up 1,337 shares - June 3, 2019

Securities to be offered to employees in employee benefit plans, post-effective amendments - May 14, 2019

Securities to be offered to employees in employee benefit plans, post-effective amendments - May 14, 2019

Halozyme Therapeutics Just Filed Its Quarterly Report: Available-for-sale m... - May 7, 2019

Halozyme: Partner Receives Fda Approval For Subcutaneous Formulation Of Herceptin - May 7, 2019

SVP of Halozyme Therapeutics just declared 0 ownership of the company. - May 6, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Amendment to Articles of Incorporation or - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

Halozyme Therapeutics director just picked up 12,173 shares - May 3, 2019

SVP of Halozyme Therapeutics just picked up 4,498 shares - April 15, 2019

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - March 22, 2019

Other definitive proxy statements - March 22, 2019

Other preliminary proxy statements - March 1, 2019

SVP of Halozyme Therapeutics just picked up 2,541 shares - Feb. 22, 2019

SVP of Halozyme Therapeutics just picked up 7,453 shares - Feb. 22, 2019

Halozyme Therapeutics's President and CEO just picked up 19,843 shares - Feb. 22, 2019

SVP of Halozyme Therapeutics just picked up 7,453 shares - Feb. 22, 2019

Halozyme Therapeutics Just Filed Its Annual Report: Available-for-sale m... - Feb. 21, 2019

SVP of Halozyme Therapeutics just disposed of 2,536 shares - Feb. 20, 2019

SVP of Halozyme Therapeutics just picked up 5,109 shares - Feb. 15, 2019

SVP of Halozyme Therapeutics just picked up 4,468 shares - Feb. 15, 2019

SVP of Halozyme Therapeutics just picked up 5,109 shares - Feb. 15, 2019

Halozyme Therapeutics's President and CEO just picked up 14,486 shares - Feb. 15, 2019

SVP of Halozyme Therapeutics was just granted 109,140 options and restricted shares - Feb. 14, 2019

Halozyme Therapeutics's President and CEO was just granted 381,397 options and restricted shares - Feb. 14, 2019

SVP of Halozyme Therapeutics was just granted 130,968 options and restricted shares - Feb. 14, 2019

SVP of Halozyme Therapeutics was just granted 109,140 options and restricted shares - Feb. 14, 2019

SVP of Halozyme Therapeutics was just granted 109,140 options and restricted shares - Feb. 14, 2019

BB Biotech AG just provided an update on share ownership of Halozyme Therapeutics - Feb. 13, 2019

The Vanguard Group just provided an update on share ownership of Halozyme Therapeutics - Feb. 11, 2019

Halozyme Therapeutics's President and CEO just picked up 16,703 shares - Feb. 6, 2019

. Iridian Asset Management LLC just provided an update on share ownership of Halozyme Therapeutics - Feb. 6, 2019

SVP of Halozyme Therapeutics just picked up 14,802 shares - Feb. 5, 2019

SVP of Halozyme Therapeutics just picked up 9,755 shares - Feb. 5, 2019

Halozyme Therapeutics's President and CEO just picked up 36,062 shares - Feb. 5, 2019

SVP of Halozyme Therapeutics just disposed of 2,503 shares - Feb. 5, 2019

BlackRock, Inc. just provided an update on share ownership of Halozyme Therapeutics - Feb. 4, 2019

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37 ANNUAL JP MORGAN HEALTHCARE CONFERENCE Anticipated ENHANZE - Jan. 9, 2019

Departure of Directors or Certain - Dec. 13, 2018

Halozyme Therapeutics director just disposed of 15,000 shares - Dec. 10, 2018

Halozyme Announces Change In Primary Endpoint For HALO-301 TO OVERALL SURVIVAL - Nov. 26, 2018

Halozyme Reports Third Quarter 2018 Financial Results - ENHANZE - Nov. 6, 2018

Halozyme Therapeutics Just Filed Its Quarterly Report: Available-for-sale m... - Nov. 6, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. UBS GLOBAL ASSET MANAGEMENT AMERICAS INC 41,058,329 N/A Dec. 31, 2019
2. VANGUARD GROUP INC 13,296,940 N/A June 30, 2019
3. BB Biotech AG 8,322,860 3.5 March 31, 2019
4. Bellevue Group AG 8,036,856 2.1 Dec. 31, 2019
5. BlackRock, Inc. 7,778,349 N/A Jan. 22, 2016
6. Third Security, LLC 7,046,385 20.2 Dec. 31, 2019
7. William Blair Investment Management, LLC 6,331,530 0.5 Dec. 31, 2019
8. Invesco Ltd. 5,387,409 N/A June 30, 2019
9. Invesco Ltd. 5,387,409 N/A June 30, 2019
10. Invesco Ltd. 5,266,794 N/A Sept. 30, 2019
11. Artisan Partners Limited Partnership 5,260,496 0.2 Dec. 31, 2019
12. JPMORGAN CHASE & CO 4,933,062 N/A June 30, 2019
13. JPMORGAN CHASE & CO 4,933,062 N/A June 30, 2019
14. Invesco Ltd. 4,728,817 N/A Dec. 31, 2019
15. Invesco Ltd. 4,728,817 N/A Dec. 31, 2019
16. Invesco Ltd. 4,728,817 N/A Dec. 31, 2019
17. BlackRock Fund Advisors 4,518,198 N/A Sept. 30, 2016
18. State Street Corp 4,490,873 N/A Dec. 31, 2019
19. SENZAR ASSET MANAGEMENT, LLC 3,830,190 12.5 Sept. 30, 2017
20. SNYDER CAPITAL MANAGEMENT L P 3,495,892 2.4 Dec. 31, 2019
21. BlackRock Institutional Trust Company, N.A. 3,035,630 N/A Dec. 31, 2016
22. TORONTO DOMINION BANK 3,000,000 N/A Dec. 31, 2019
23. Pictet Asset Management Ltd 2,868,926 0.1 Dec. 31, 2019
24. JPMORGAN CHASE & CO 2,868,670 N/A Sept. 30, 2017
25. FMR LLC 2,344,593 N/A Dec. 31, 2019
26. D. E. Shaw & Co., Inc. 2,075,223 N/A Dec. 31, 2019
27. NORTHERN TRUST CORP 1,850,077 N/A June 30, 2018
28. GEODE CAPITAL MANAGEMENT, LLC 1,824,500 N/A Sept. 30, 2019
29. NORTHERN TRUST CORP 1,782,098 N/A March 31, 2019
30. NORGES BANK 1,708,271 N/A Dec. 31, 2019

Halozyme Therapeutics (HALO)

140
 


Feedback